Echinacea angustifolia extract

Echinacea angustifolia extract is a complex botanical mixture derived from the narrow-leaf coneflower, primarily utilized for its immunomodulatory and anti-inflammatory properties (NIH NCCIH, 2020). It is not a discrete molecular target but rather a therapeutic agent containing multiple bioactive constituents, including alkamides, caffeic acid derivatives like echinacoside, and polysaccharides (Bauer, 1999). These components exert their effects by modulating the immune system, specifically through the activation of cannabinoid receptor type 2 (CB2) and the stimulation of phagocytosis in macrophages (Raduner et al., 2006). The extract is commonly used in the prevention and treatment of upper respiratory tract infections, such as the common cold, by influencing cytokine signaling pathways (StatPearls, 2023). Because it acts as an immunostimulant, its use is often cautioned in patients with autoimmune disorders or those taking immunosuppressive medications (EMA, 2015). Furthermore, its pharmacological profile is characterized by a multi-target approach, affecting various enzymes and receptors simultaneously rather than a single pathway. Clinical efficacy remains a subject of ongoing research, with variability in results often attributed to differences in extraction methods and plant parts used (NIH NCCIH, 2020).

Other names

Narrow-leaf coneflower extractBlacksamson echinacea extractEchinacea angustifolia root extractNarrow-leaved purple coneflower extract

The mechanism of action involves the modulation of the innate and adaptive immune systems through multiple pathways. Alkamides within the extract act as ligands for the cannabinoid receptor type 2 (CB2), which is primarily expressed on immune cells, leading to immunomodulatory and anti-inflammatory effects (Raduner et al., 2006). Additionally, the extract stimulates macrophage activity and phagocytosis, and influences the production of pro-inflammatory cytokines such as TNF-alpha and IL-1 beta (Bauer, 1999; StatPearls, 2023). It also demonstrates weak inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, contributing to its anti-inflammatory profile (Huss et al., 2002).